Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017046 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL13096289 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL22058769 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL22059479 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23323248 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23332629 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL24936522 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23719677 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL20990354 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL19767510 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | ALDH1A1 2585/4885THRB 2090/4885MAPK1 4499/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | ALDH1A1 4243/4885THRB 3746/4885MAPK1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.